Structural Basis of Drug Discovery Targeting SK Channels for Amyotrophic Lateral Sclerosis
Chapman access only poster or presentation
Amyotrophic lateral sclerosis, (ALS) is a devastating progressive neuromuscular disease. Neurodegeneration of motor neurons in the motor cortex and the brainstem/spinal cord causes the patient with ALS to slowly lose motor function and eventually completely paralyzed. It is known that hyperexcitability has an inverse correlation with the survival of ALS patients. Positive modulation of potassium channels reduces hyperexcitability and improves survival of motor neurons. Therefore it can be assumed that by reducing hyperexcitability, progression of ALS in patients can be delayed. Riluzole is the only FDA approved drug used to treat ALS. Small conductance calcium activated potassium (SK) channels are among the drug targets of riluzole. We determined the crystal structure of riluzole and its binding pocket in SK2 chanel. By analyzing the specifics of the interaction of riluzole with SK channels, increase in efficacy and better treatment in ALS patients can be acquired.
Alexander, Tia, "Structural Basis of Drug Discovery Targeting SK Channels for Amyotrophic Lateral Sclerosis" (2015). Student Scholar Symposium Abstracts and Posters. 85.